Olopatadine nasal spray for the treatment of allergic rhinitis.

Article Details

Citation

Copy to clipboard

Roland PS, Marple BF, Wall GM

Olopatadine nasal spray for the treatment of allergic rhinitis.

Expert Rev Clin Immunol. 2010 Mar;6(2):197-204.

PubMed ID

20402382 [ View in PubMed

]

Abstract

Olopatadine hydrochloride nasal spray (Patanase Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Olopatadine	Histamine H1 receptor	Protein	Humans	Yes	Antagonist	Details